Company intelligence / Profile preview
AlphaMa Biotech
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
Overview
Suzhou AlphaMa Biotechnology Co., Ltd. (AlphaMa Biotech) is a drug research and development company driven by big data and artificial intelligence (AI). Founded in 2018 and based in Suzhou, China, the company integrates DNA-encoded library (DEL) screening with AI to establish its proprietary Intelligent DEL (iDEL) platform. AlphaMa focuses on data-driven lead compound discovery, multi-target selectivity, and ADME/T optimization. The company is developing a pipeline of innovative small molecule drugs targeting cancerous, neurological, metabolic, and infectious diseases, and has established key partnerships with major pharmaceutical companies like Eli Lilly, Simcere, and Zai Lab.
- Therapeutic areas
- NeurologyOncologyInfectious DiseasesMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on AlphaMa Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlphaMa Biotech.